From Ex Vivo to In Vivo : Advances in Lentiviral Vector Engineering for CAR-T Therapy

Immune Network · Published 2026-01-01 · DOI 10.4110/in.2026.26.e13

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.4110/in.2026.26.e13

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Delivery platforms for in vivo CAR-T engineering · Frontiers in Immunology · 2026 · Cites or is cited by this article
• Cascading Attrition of In Vivo CAR-T Therapy: From Systemic Delivery Failure to Functional Collapse · Critical Reviews in Oncology/Hematology · 2026 · Cites or is cited by this article
• Regulatory T Cell Metabolism: A Promising Therapeutic Target for Cancer Treatment? · Immune Network · 2025 · Same journal
• Complement Anaphylatoxin C5a-Induced Mouse Lymphatic Functions Modulate Interactions Between Endothelial Cells and T Lymphocytes · Immune Network · 2026 · Same journal
• Aromatic Amino Acid Metabolites: Molecular Messengers Bridging Immune-Microbiota Communication · Immune Network · 2025 · Same journal
• Novel STAT3 Y360C Gain-of-function Variant Underlies Immune Dysregulation and Aberrancy in Mitochondrial Dynamics · Immune Network · 2025 · Same journal
• Unlocking IL-33: New Insights into Tumor Immunity · Immune Network · 2025 · Same journal
• VISTA: An Emerging Immune Checkpoint With Clinical Relevance Across Diverse Malignancies · Immune Network · 2025 · Same journal
• Tissue-Resident ILC2s Across Organs: Heterogeneity, Niche Crosstalk, and Shared Regulatory Circuits · Immune Network · 2025 · Same journal
• In Search of Adaptive-Like Features of NK Cells Co-Expressing NKG2C and NKG2A · Immune Network · 2026 · Same journal